Announced details
Adenovirus infections after hematopoietic stem cell transplantation (UK)
45 patients enrolled in a global Phase 3 clinical trial as of the end of October 2026
The relationship between the regulatory authority and the applicant concerning BCV's marketing authorisation application in the UK.
An agency under the UK's Department of Health and Social Care. It is the executive agency responsible for the authorisation and safety of medicines and medical devices.
No impact on the consolidated earnings outlook for the fiscal year ending December 2026
The company does not address Contract Value / Offering price.
ID Week 2024 (Infectious Diseases Society of America Week), press release dated 23 October 2024
| Item | Details |
|---|---|
| Names of Products / Services Covered | Brincidofovir (BCV, SyB V-1901 injection) |
| Counterparty | Medicines and Healthcare products Regulatory Agency (MHRA) |
| Counterparty overview | An agency under the UK's Department of Health and Social Care. It is the executive agency responsible for the authorisation and safety of medicines and medical devices. |
| Relationship with the Company | The relationship between the regulatory authority and the applicant concerning BCV's marketing authorisation application in the UK. |
| Applicable area | Adenovirus infections after hematopoietic stem cell transplantation (UK) |
| Usage history | 45 patients enrolled in a global Phase 3 clinical trial as of the end of October 2026 |
| Impact on Business Performance | No impact on the consolidated earnings outlook for the fiscal year ending December 2026 |
| Source | ID Week 2024 (Infectious Diseases Society of America Week), press release dated 23 October 2024 |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because recognition grew that BCV could become an important treatment option in a disease area involving severe conditions with extremely limited treatment options.